Global /China /Healthcare /Drug Manufacturers - General /2595

GenFleet Therapeutics (Shanghai) Inc.

2595

• SHEK: 2595 • Delayed

43.00HKD 1.6%

5.49 USD

As of 14 June 2026, GenFleet Therapeutics (Shanghai) Inc. has a market cap of $2.0B USD, ranking #7044 globally and #1721 in China. It ranks #564 in the Healthcare sector, and #220 in the Drug Manufacturers - General industry.

Global Rank

7044

Country Rank

1721

Sector Rank

564

Industry Rank

220

Key Stats

Market Cap

$2.0BUSD

15.67B HKD

Enterprise Value

$1.72BUSD

13.48B HKD

Revenue (TTM)

$18.5MUSD

144.96M HKD

EBITDA (TTM)

-$38.99MUSD

-305.5M HKD

Net Income (TTM)

-$254.8MUSD

-2.0B HKD

EBITDA Margin

-211%

PS Ratio

108.1

PB Ratio

7.8

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jiong Lan open_in_new

Founded

2017

Website

genfleet.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.6%	-9.4%	29%	38%	50%	78%	-36%	-36%	-36%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	2595 ISIN: CNE1000074L2 Shares Out.: Shares Outstanding: 338.029M¹ Shares Float: 193.836M² TV: TradingView: HKEX: 2595 SA: Stock Analysis: HKG: 2595 YF: Yahoo Finance: 2595.HK GF: Google Finance: HKG: 2595 BA: Barron's: 2595 MS: Morningstar: XHKG: 02595	43.00 HKD	TV: TradingView: HKEX: 2595 SA: Stock Analysis: HKG: 2595 YF: Yahoo Finance: 2595.HK GF: Google Finance: HKG: 2595 BA: Barron's: 2595 MS: Morningstar: XHKG: 02595

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About GenFleet Therapeutics (Shanghai) Inc.

GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. The company was incorporated in 2017 and is based in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.85B 364.89B CNY 3K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.64B 336.36B CNY 2K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 1K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 840%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.51B 111.89B CNY 726%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 700%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 38K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 27K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 18K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 16K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 14K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 14K%	20.5	Switzerland

chevron_leftBack